Francis Lo, Chief People Officer of Adaptive Biotechnologies (ADPT), has been a consistent seller of company stock over the past year, with Form 4 filings showing 39 total transactions and no open-market purchases. The aggregate sell value across all filings reached approximately $9.9 million, while the officer reported zero dollars in acquired shares through open-market buys. The most recent activity, clustered in July 2026, shows a clear pattern: on July 15, Lo sold shares worth $2.39 million, following a $1.01 million sale on July 2 and two separate sales on July 1 totaling roughly $1.14 million. These transactions were paired with option exercises (coded M) on the same dates, a mechanical step that typically precedes a sale.
The selling bias is unambiguous. Over the trailing eight transactions, all were sales or option exercises, with no purchases. The largest single disposition was the July 15 sale of $2.39 million, and the smallest recent sale was $193,919.74 on July 1. Earlier in the year, Lo sold $695,070.09 on June 4, $340,039.48 on April 8, and $430,749.44 on March 11, with a $574,536.66 sale on March 5. The only non-sale transaction in the recent window was a March 4 grant (coded A) valued at $0, which is compensation rather than a discretionary buy.
The pattern—recurring sales, no purchases, and consistent option exercises—indicates a steady liquidation of equity in ADPT. The dollar values are substantial, and the frequency (multiple sales per month in July) suggests an ongoing program rather than a one-off event. While the filings do not disclose motive, the data shows a clear directional bias toward selling, with total sell value exceeding $9.8 million against zero buy value.
AI-assisted summary